Theravance Biopharma (TBPH) News Today $10.67 +0.10 (+0.95%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$10.68 +0.01 (+0.05%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Theravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" RatingWall Street Zen upgraded shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday.June 21, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives $11.33 Average PT from AnalystsJune 20, 2025 | americanbankingnews.comJones Trading Initiates Coverage on Theravance Biopharma (NASDAQ:TBPH)June 19, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Still a Buy?Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Time to Buy?June 17, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Hold" from AnalystsShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the four research firms that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and oneJune 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from Analysts at Jones TradingJones Trading began coverage on Theravance Biopharma in a report on Tuesday. They set a "buy" rating and a $24.00 target price for the company.June 17, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - What's Next?Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above 50 Day Moving Average - Here's WhyJune 17, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 27.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 150,039 shares oJune 9, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 24,000 SharesTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 24,000 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the transaction, the senior vice president now directly owns 336,918 shares of the company's stock, valued at $3,706,098. This represents a 6.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.June 5, 2025 | marketbeat.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of StockJune 5, 2025 | insidertrades.comPublic Employees Retirement System of Ohio Takes $353,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Public Employees Retirement System of Ohio acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 37,461 shares of the biopharJune 5, 2025 | marketbeat.comSquarepoint Ops LLC Sells 51,783 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Squarepoint Ops LLC lessened its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 52.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 47,168 shares of the biopharmaceutical company's stock after selling 5June 5, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Hits New 52-Week High - Time to Buy?Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High - Still a Buy?June 3, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLCMillennium Management LLC increased its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 71.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 192,839 shares of the biopharmaceutical cJune 3, 2025 | marketbeat.comTheravance Shares Rise Premarket on Sale of Trelegy RoyaltiesJune 2, 2025 | marketwatch.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...June 2, 2025 | gurufocus.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 ...June 2, 2025 | gurufocus.comTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 MillionJune 2, 2025 | prnewswire.comNuveen Asset Management LLC Buys 48,635 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Nuveen Asset Management LLC increased its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 495,727 shares of the biopharmaceutical company's stock afJune 1, 2025 | marketbeat.comJane Street Group LLC Has $493,000 Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Jane Street Group LLC lessened its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 63.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,344 shares of the biopharmaceutical companyMay 31, 2025 | marketbeat.comTheravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and AmpreloxetineMay 21, 2025 | investing.comD. E. Shaw & Co. Inc. Grows Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)D. E. Shaw & Co. Inc. raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 833,943 shares of the biopharmaceutical companMay 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Cuts Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Jacobs Levy Equity Management Inc. lessened its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 23.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 438,463 shares of the biopharmaceuticMay 17, 2025 | marketbeat.comNewtyn Management LLC Grows Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Newtyn Management LLC increased its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 5.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,757,403 shares of the biopharmaceutical company's sMay 16, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Dimensional Fund Advisors LP grew its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 20.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 553,713 shares of the biopharmaceMay 15, 2025 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMay 13, 2025 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Collegium Pharmaceutical (COLL) and Theravance Biopharma (TBPH)May 11, 2025 | theglobeandmail.comEarnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecastMay 10, 2025 | uk.investing.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comTheravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comTheravance Biopharma Announces Ampreloxetine Presentations at the International MSA CongressMay 9, 2025 | prnewswire.comCorton Capital Inc. Purchases Shares of 33,346 Theravance Biopharma, Inc. (NASDAQ:TBPH)Corton Capital Inc. acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,346 shares of the biopharmaceutical comMay 9, 2025 | marketbeat.comTheravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comPDT Partners LLC Sells 49,501 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)PDT Partners LLC trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 56.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,676 shares of the biopharmaceutical company'sMay 5, 2025 | marketbeat.comMarshall Wace LLP Has $622,000 Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)Marshall Wace LLP decreased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 56.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,067 shares of the bioMay 5, 2025 | marketbeat.comTheravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on ThursdayTheravance Biopharma (NASDAQ:TBPH) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-theravance-biopharma-inc-stock/)May 3, 2025 | marketbeat.comPark West Asset Management LLC Cuts Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Park West Asset Management LLC trimmed its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 3.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,792,988 shares of the biopharmaceutical compMay 1, 2025 | marketbeat.comZacks Research Issues Positive Outlook for TBPH EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research boosted their Q1 2027 earnings estimates for Theravance Biopharma in a report issued on Wednesday, April 23rd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.40)April 29, 2025 | marketbeat.comTheravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA CongressApril 28, 2025 | prnewswire.comRep. George Whitesides Sells Theravance Biopharma, Inc. (NASDAQ:TBPH) StockRepresentative George Whitesides (D-California) recently sold shares of Theravance Biopharma, Inc. (NASDAQ:TBPH). In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Theravance Biopharma stock on March 24th. The trade occurred in the RApril 28, 2025 | marketbeat.comJPMorgan Chase & Co. Reduces Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)JPMorgan Chase & Co. trimmed its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 219,568 shares of the biopharmaceutical company's stockApril 27, 2025 | marketbeat.comTheravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | prnewswire.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 4,000 Shares of StockApril 24, 2025 | insidertrades.comVanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)Vanguard Group Inc. lessened its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,010,544 shares of the biopharmaceutical company's stock after selling 41,145 sApril 19, 2025 | marketbeat.comTrexquant Investment LP Buys 50,826 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Trexquant Investment LP increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 50.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,083 shares of the biopharmaceutical company's stApril 12, 2025 | marketbeat.comTheravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual MeetingApril 7, 2025 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMarch 31, 2025 | prnewswire.comTheravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of NeurologyMarch 27, 2025 | prnewswire.comQ1 EPS Forecast for Theravance Biopharma Reduced by AnalystTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Theravance Biopharma in a report released on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical companMarch 24, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from AnalystsShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given a consensus rating of "Hold" by the five analysts that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendatioMarch 23, 2025 | marketbeat.com Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Media Mentions By Week TBPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼0.780.62▲Average Medical News Sentiment TBPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼32▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KNSA News AGIO News SRPT News IDYA News INDV News BLTE News GLPG News HRMY News FOLD News SUPN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
